Just cutting and pasting from Bear's post on the Yale Club presentation seeing as its a current topic of conversation....going to interesting to see if this has been cancelled like the AGMs.

Resverlogix’s R&D Update with World-Renowned Key Opinion Leaders

Thursday, October 13, 2016 12:00PM – 2:15PM EST

Lunch and Presentations will start at 12:15

The Yale Club of NYC, Roof Top Restaurant

22nd Floor 50 Vanderbilt Avenue at 44th St.

Featuring Presentations from Key Opinion Leaders:

Professor Kausik Ray, MBCHB, MD, MPHIL, FACC, FAHA, FESC, FRCP. Professor of Public Health, Department of Primary Care and Public Health, School of Public Health, Imperial College London, UK. Chairman, Resverlogix BETonMACE Clinical Steering Committee.

Dr. Kamyar Kalantar-Zadeh, MD, MPH, PhD. Professor of Medicine, Epidemiology, Pediatrics and Public Health, University of California, Irvine School of Medicine. Chairman, Resverlogix Renal Clinical Advisory Board.

One American dies every 40 seconds of cardiovascular disease. Diabetic patients have a 2-4 times higher death rate and 68% of people with diabetes over the age of 65 will die from heart disease even if their glucose is well managed. By 2030, the total projected economic burden and direct costs of cardiovascular disease in the U.S. is estimated at $918B annually. We hope you will attend the event to hear from world leading experts on the latest technologies of how this grievous disease burden is being addressed.

Resverlogix Corp. (TSE:RVX) is a leading biotechnology company developing novel drugs for the treatment of high-risk cardiovascular disease, diabetes mellitus and chronic kidney disease via ‘epigenetics’ - modifications of gene expression without altering DNA sequence. Their lead drug candidate apabetalone (RVX-208) is currently in a Phase 3 clinical trial ‘BETonMACE’ for high-risk cardiovascular disease patients with T2 diabetes mellitus to reduce the incidence of Major Adverse Cardiac Events (MACE) in this sick patient group. 15% of patients will also have renal disease. MACE in the BETonMACE study is defined as cardiovascular death, non-fatal myocardial infarction or stroke.

Resverlogix Presenters:

Mr. Donald J. McCaffrey, President and CEO, Co-Founder

Dr. Michael Sweeney, M.D., Senior Vice President of Clinical Development

Dr. Ewelina Kulikowski, Ph.D., Senior Vice President of Research & Development

RSVP

The event is intended for investors, sell-side analysts, investment bankers and business development professionals. Please RSVP in advance if you plan to attend, as space is limited:

Susan A. Noonan

S.A. Noonan Communications, LLC

Phone: +1 (212) 966-3650

Email: susan@sanoonan.com